Shilpa Medicare's revenue increased 44.7% YoY
  • 06 Nov 2026
  • Shilpa Medicare Ltd reported a 14.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 44.7%.
  • Its expenses for the quarter were up by 15.1% QoQ and 41.2% YoY.
  • The net profit decreased 21.5% QoQ and increased 79.7% YoY.
  • The earnings per share (EPS) of Shilpa Medicare Ltd stood at 4.05 during Q2 FY 2026-27.

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Shilpa Medicare Ltd is a pharmaceutical company known for its manufacturing and development of a wide range of pharmaceutical products. The company is primarily focused in the pharmaceutical industry, with a strong emphasis on the creation of complex generics and active pharmaceutical ingredients (APIs). Shilpa Medicare Ltd also engages in the development of novel drug delivery systems and has a commitment to research and innovation within its sector. While specific recent developments are not provided here, pharmaceutical companies like Shilpa Medicare often engage in activities such as expanding product lines, enhancing R&D capabilities, and forming strategic partnerships to drive growth.

The total income for Shilpa Medicare Ltd in Q2FY27 was ₹537.77 crores, marking a significant increase of 14.7% quarter-over-quarter (QoQ) from ₹468.91 crores in Q1FY27. Year-over-year (YoY), the total income rose by 44.7% from ₹371.72 crores in Q2FY26. This growth in revenue reflects a substantial enhancement in the company's ability to generate sales over both the preceding quarter and the same quarter in the prior year. The notable increase in revenue over these periods suggests an expansion in the company's market reach or product offerings.

In terms of profitability, the profit before tax in Q2FY27 amounted to ₹103.63 crores, up 12.5% QoQ from ₹92.09 crores in Q1FY27 and a considerable 60.6% increase YoY from ₹64.54 crores in Q2FY26. The tax expense for Q2FY27 was ₹24.34 crores, which shows a dramatic shift from the previous quarter's tax credit of ₹-2.83 crores, and a 19.5% increase from the ₹20.36 crores tax in Q2FY26. Consequently, the profit after tax for Q2FY27 was ₹79.18 crores, which decreased by 21.5% QoQ from ₹100.88 crores in Q1FY27 but increased by 79.7% YoY from ₹44.07 crores in Q2FY26. Earnings per share followed a similar pattern, at ₹4.05 in Q2FY27, down from ₹5.16 in Q1FY27, but up from ₹2.25 in Q2FY26, reflecting the fluctuations in net profitability.

The total expenses for Q2FY27 were ₹433.71 crores, showing a 15.1% increase QoQ from ₹376.82 crores in Q1FY27 and a 41.2% increase YoY from ₹307.18 crores in Q2FY26. This rise in expenses is consistent with the significant increase in total income, indicating higher operational costs associated with increased business activity. The elevated expenses could be attributed to factors such as expanded operations, increased production costs, or investments in research and development. The operations during this quarter demonstrate a balance between rising income and associated expenses, maintaining a robust operational structure in line with the company’s growth trajectory.

Shilpa Medicare Ltd announced its Q2 FY 2026-27 results on 6 November, 2026.

Shilpa Medicare Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.

Key highlights of Shilpa Medicare Ltd Q2 FY 2026-27 results include:

  • Revenue: ₹537.77 crore
  • Net Profit: ₹79.18 crore
  • EBITDA: ₹150.60 crore
  • Year-over-Year Growth: 44.7%
  • Quarter-over-Quarter Growth: 14.7%

Shilpa Medicare Ltd reported a net loss of ₹79.18 crore in Q2 FY 2026-27, reflecting a 79.7% year-over-year growth.

Shilpa Medicare Ltd posted a revenue of ₹537.77 crore in Q2 FY 2026-27.